JOP20200128A1 - صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها - Google Patents

صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها

Info

Publication number
JOP20200128A1
JOP20200128A1 JOP/2020/0128A JOP20200128A JOP20200128A1 JO P20200128 A1 JOP20200128 A1 JO P20200128A1 JO P20200128 A JOP20200128 A JO P20200128A JO P20200128 A1 JOP20200128 A1 JO P20200128A1
Authority
JO
Jordan
Prior art keywords
pyrimidinylamino
polymorphs
production
methods
solid forms
Prior art date
Application number
JOP/2020/0128A
Other languages
English (en)
Inventor
Anantha Sudhakar
Travis Remarchuk
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JOP20200128A1 publication Critical patent/JOP20200128A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بصورة متعددة الأشكال متبلرة وصور غير متبلرة من 2-ميثيل-2-(3-ميثيل-4-(4-(ميثيل أمينو)-5-(تراي فلورو ميثيل)بيريميدين-2-يل أمينو)-1H-بيرازول-1-يل)بروبان نيتريل أو ذوابات، أشكال صنوية، وأملاح أو بلورات مشتركة مقبولة صيدليًا منها، وعمليات لتحضيرها. الشكل 1
JOP/2020/0128A 2017-11-21 2018-11-20 صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها JOP20200128A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589276P 2017-11-21 2017-11-21
PCT/US2018/062102 WO2019104086A1 (en) 2017-11-21 2018-11-20 Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

Publications (1)

Publication Number Publication Date
JOP20200128A1 true JOP20200128A1 (ar) 2020-05-21

Family

ID=66631734

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0128A JOP20200128A1 (ar) 2017-11-21 2018-11-20 صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها

Country Status (22)

Country Link
US (3) US10370361B2 (ar)
EP (1) EP3717473B1 (ar)
JP (1) JP7303821B2 (ar)
KR (1) KR20200089713A (ar)
CN (1) CN111819174A (ar)
AR (1) AR113893A1 (ar)
AU (1) AU2018372180B2 (ar)
BR (1) BR112020010215A2 (ar)
CA (1) CA3083022A1 (ar)
CL (1) CL2020001346A1 (ar)
CO (1) CO2020006206A2 (ar)
CR (1) CR20200216A (ar)
EA (1) EA202091279A1 (ar)
IL (1) IL274824A (ar)
JO (1) JOP20200128A1 (ar)
MA (1) MA51222A (ar)
MX (1) MX2020005332A (ar)
PE (1) PE20210157A1 (ar)
SG (1) SG11202004733WA (ar)
TW (1) TWI823878B (ar)
UA (1) UA126414C2 (ar)
WO (1) WO2019104086A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717473B1 (en) 2017-11-21 2024-01-10 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
WO2019126383A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
WO2023174946A1 (en) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Early and non-invasive method for assessing a subject's risk of having parkinson's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
SI2576541T1 (sl) 2010-06-04 2016-07-29 F. Hoffmann-La Roche Ag Aminopirimidinski derivati kot modulatorji lrrk2
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
NO2638031T3 (ar) 2010-11-10 2018-03-10
ES2638595T3 (es) 2011-11-29 2017-10-23 Genentech, Inc. Derivados de aminopirimidina como moduladores de LRRK2
US8796296B2 (en) 2011-11-29 2014-08-05 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
JP6180426B2 (ja) 2011-11-29 2017-08-16 ジェネンテック, インコーポレイテッド パーキンソン病の処置のためのキナーゼlrrk2モジュレーターとしての2−(フェニル又はピリド−3−イル)アミノピリミジン誘導体
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
KR102091895B1 (ko) 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
KR102091894B1 (ko) * 2012-05-03 2020-03-20 제넨테크, 인크. Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
MD3472153T2 (ro) * 2016-06-16 2022-03-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1H-pirazoli în calitate de inhibitori L RRK2 pentru utilizare în tratamentul tulburărilor neurodegenerative
EP3717473B1 (en) * 2017-11-21 2024-01-10 Denali Therapeutics Inc. Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

Also Published As

Publication number Publication date
SG11202004733WA (en) 2020-06-29
US20190194170A1 (en) 2019-06-27
EP3717473A1 (en) 2020-10-07
BR112020010215A2 (pt) 2020-11-03
US11427571B2 (en) 2022-08-30
US20210087176A1 (en) 2021-03-25
TW201925190A (zh) 2019-07-01
MA51222A (fr) 2020-10-07
KR20200089713A (ko) 2020-07-27
WO2019104086A1 (en) 2019-05-31
JP2021504450A (ja) 2021-02-15
MX2020005332A (es) 2021-01-08
TWI823878B (zh) 2023-12-01
PE20210157A1 (es) 2021-01-26
UA126414C2 (uk) 2022-09-28
AR113893A1 (es) 2020-06-24
US10370361B2 (en) 2019-08-06
CR20200216A (es) 2021-03-19
EP3717473B1 (en) 2024-01-10
IL274824A (en) 2020-07-30
EA202091279A1 (ru) 2020-08-19
CL2020001346A1 (es) 2020-11-20
CN111819174A (zh) 2020-10-23
EP3717473A4 (en) 2021-07-07
JP7303821B2 (ja) 2023-07-05
US20190315723A1 (en) 2019-10-17
AU2018372180B2 (en) 2023-08-17
AU2018372180A1 (en) 2020-06-18
CO2020006206A2 (es) 2020-08-10
CA3083022A1 (en) 2019-05-31
US10851088B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
PH12018550120A1 (en) Steroid derivative fxr agonist
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
WO2015132799A3 (en) Heterocyclic compounds
MY199931A (en) 3-substituted propionic acids as alpha v integrin inhibitors
MX2016013564A (es) Inhibidores heterociclicos de cinasas.
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
EA201791304A1 (ru) Производные изохинолина для лечения вич
MD3882250T2 (ro) Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK
JOP20200128A1 (ar) صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
MX2019015886A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-0xoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12016501903A1 (en) Novel fused imidazobenzothiazole compounds
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
PH12017501532A1 (en) Crystalline forms of a pyrrolopyridine compound
PH12017500323B1 (en) P38 map kinase inhibiting indanyl urea compounds
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
HK1221225A1 (zh) -二氨基吡唑激酶抑制劑的藥學上可接受的鹽
WO2015102017A8 (en) Processes for the preparation of lorcaserin
ZA202008062B (en) Pharmaceutically acceptable salts of sepiapterin
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
MX2021014705A (es) Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.